Roundtable Discussion: Taking Learnings from CAR-T Therapies & Moving On to T-Cell Engagers in Autoimmunity to Leverage Improved Safety, Efficacy, & Reduced CRS
Time: 5:00 pm
day: Day One
Details:
- Translating precision targeting from CAR-T to TCEs for safer autoimmune therapies. Exploring how the antigen specificity and conditional activation lessons from CAR-Ts can be applied to TCE design to minimize off-target effects and reduce immunerelated toxicities in non-malignant settings
- Designing TCEs to mimic CAR-T persistence by discussing strategies to optimize TCE half-life and tissue distribution for durable disease control without the prolonged and potential unpredictable persistence risks associated with CAR-T in autoimmune patients
- Minimizing CRS in non-oncology indications by comparing the incidence and management of CRS in CAR-T vs. TCE approaches and highlighting how affinity tuning, dose fractionation, and masking technologies from CAR-T development are informing safer TCE constructs
- Reimagining patient access: Contrast the logistical and cost-intensive nature of CAR-T with the potential of TCEs as off-the-shelf, subcutaneously administered, or outpatient-suitable therapies, broadening access to autoimmune patients globally
